Average body weight fell between 13.6% and 19.7% across drug doses compared with 2.0% on placebo over 24 weeks.Average body weight fell between 13.6% and 19.7% across drug doses compared with 2.0% on placebo over 24 weeks.
Adding a GLP-1 receptor agonist was linked to lower rates of major adverse kidney events (HR 0.70) compared with SGLT2 inhibitor monotherapy over 12 months.Adding a GLP-1 receptor agonist was linked to lower rates of major adverse kidney events (HR 0.70) compared with SGLT2 inhibitor monotherapy over 12 months.